Dario A. Paggiarino - 30 Mar 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
30 Mar 2024
Net transactions value
-$528,036
Form type
4
Filing time
02 Apr 2024, 17:27:52 UTC
Previous filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +5,834 +14% $0.000000 48,056 30 Mar 2024 Direct
transaction EYPT Common Stock Options Exercise $0 +30,570 +64% $0.000000 78,626 30 Mar 2024 Direct
transaction EYPT Common Stock Options Exercise $0 +14,000 +18% $0.000000 92,626 30 Mar 2024 Direct
transaction EYPT Common Stock Tax liability $320,240 -15,493 -17% $20.67 77,133 30 Mar 2024 Direct F1
transaction EYPT Common Stock Tax liability $61,121 -2,957 -3.8% $20.67 74,176 30 Mar 2024 Direct F1
transaction EYPT Common Stock Tax liability $146,674 -7,096 -9.6% $20.67 67,080 30 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -30,570 -100% $0.000000* 0 30 Mar 2024 Common Stock 30,570 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -5,834 -100% $0.000000* 0 30 Mar 2024 Common Stock 5,834 $0.000000 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -14,000 -100% $0.000000* 0 30 Mar 2024 Common Stock 14,000 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Dario A. Paggiarino is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
F3 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4 The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.